Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Glaukos's gross profit for the
three
months ended in Mar. 2026 was $117.2 Mil. Glaukos's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was $317.6 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Glaukos's gross profit for the
three
months ended in Mar. 2026 was $117.2 Mil. Glaukos's Revenue for the
three
months ended in Mar. 2026 was $150.6 Mil. Therefore, Glaukos's Gross Margin % for the quarter that ended in Mar. 2026 was 77.86%.
Glaukos had a gross margin of 77.86% for the quarter that ended in Mar. 2026 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Glaukos was 86.78%. The lowest was 55.72%. And the median was 76.67%.
Warning Sign:
Glaukos Corp gross margin has been in long-term decline. The average rate of decline per year is -1.1%.
Glaukos (NYSE:GKOS) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Glaukos had a gross margin of 77.86% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Glaukos Gross Profit Related Terms
Glaukos Gross Profit Historical Data
* Premium members only.
The historical data trend for Glaukos's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Glaukos's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glaukos Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Gross Profit distribution charts can be found below:
* The bar in red indicates where Glaukos's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $317.6 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Glaukos (GKOS) has a Gross Profit of $317.6 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Glaukos and its competitors.
Is Glaukos' Gross Profit too high?
Glaukos' current Gross Profit is $317.6 Mil. Overall, Glaukos has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Gross Profit compare to BIO and BRKR?
Glaukos' Gross Profit of $317.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Glaukos and its competitors. Glaukos's current Gross Profit is $317.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Modestly Overvalued. The stock's GF Value™ is $136.79, compared to a current price of $155.21 — trading 13.5% above its estimated fair value. The current Gross Profit is $317.6 Mil. Glaukos' overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Glaukos (GKOS), the current Gross Profit is $317.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glaukos (GKOS) Overvalued in 2026?
Based on GuruFocus' analysis, Glaukos stock appears to be overvalued.
The current stock price of $155.21 is trading 13.5% above its estimated GF Value™ of $136.79.
GuruFocus considers Glaukos to be Modestly Overvalued.
Key valuation signals for GKOS:
Gross Profit: $317.6 Mil
GF Value™: $136.79 vs. price of $155.21 (13.5% above fair value)
No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
79GF Score
Get the complete analysis for GKOS
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GKOS has been successfully added to your 
